Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Oct 31;10(5):e2100789.
doi: 10.9745/GHSP-D-21-00789. Print 2022 Oct 31.

What Have We Learned? Implementation of a Shared Learning Agenda and Access Strategy for the Hormonal Intrauterine Device

Affiliations

What Have We Learned? Implementation of a Shared Learning Agenda and Access Strategy for the Hormonal Intrauterine Device

Kate H Rademacher et al. Glob Health Sci Pract. .

Abstract

In 2015, a global learning agenda for the hormonal intrauterine device (IUD) was developed with priority research questions regarding use of the method in low- and middle-income countries. In addition, members of the Hormonal IUD Access Group aligned on a strategy to expand access in the context of volunteerism and contraceptive method choice. This article synthesizes evidence generated since then and describes steps taken to address demand- and supply-side barriers to access. Findings demonstrated high continuation rates and satisfaction among hormonal IUD users that are comparable to other long-acting reversible contraceptives (LARCs). Across studies, a sizable number of users reported they would have chosen a short-acting method or no method at all if the hormonal IUD were not an option, which suggests that women did not see the hormonal IUD as interchangeable with other LARC options and thus it may fill an important niche in the market. With several countries now poised to scale up the method, resource mobilization will be key. On the demand side, investments in implementation research will be critical to understanding how best to launch and scale the method, while ensuring the sustainability of multiple quality-assured suppliers with affordable public-sector pricing will be necessary on the supply side.

PubMed Disclaimer

References

    1. World Health Organization (WHO). WHO Statement on Levonorgestrel-Releasing Intrauterine Device Nomenclature. WHO; 2021. Accessed August 7, 2021. https://www.who.int/publications/i/item/9789240021730
    1. Rademacher KH, Sripipatana T, Pfitzer A, et al. A global learning agenda for the levonorgestrel intrauterine system (LNG IUS): addressing challenges and opportunities to increase access. Glob Health Sci Pract. 2018;6(4):635–643. 10.9745/GHSP-D-18-00383. - DOI - PMC - PubMed
    1. Hubacher D. The levonorgestrel intrauterine system: reasons to expand access to the public sector of Africa. Glob Health Sci Pract. 2015;3(4):532–537. 10.9745/GHSP-D-15-00178. - DOI - PMC - PubMed
    1. Jacobstein R, Shelton JD. The levonorgestrel intrauterine system: a pragmatic view of an excellent contraceptive. Glob Health Sci Pract. 2015;3(4):538–543. 10.9745/GHSP-D-15-00330. - DOI - PMC - PubMed
    1. Rademacher KH, Solomon M, Brett T, et al. Expanding access to a new, more affordable levonorgestrel intrauterine system in Kenya: service delivery costs compared with other contraceptive methods and perspectives of key opinion leaders. Glob Health Sci Pract. 2016;4(Suppl 2):S83–S93. 10.9745/GHSP-D-15-00327. - DOI - PMC - PubMed

Publication types

Substances

LinkOut - more resources